Valuation: Inotiv, Inc.

Market Cap 387K 340K 318K 292K 546K 37.09M 559K 3.77M 1.47M 18.36M 1.45M 1.42M 63.45M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 385M 359M 330M 617M 41.95B 632M 4.26B 1.67B 20.76B 1.64B 1.61B 71.76B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.32%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
Current month+7.77%
1 month+0.91%
3 months-96.41%
6 months-97.84%
Current year-98.03%
1 month 0.01
Extreme 0.01
0.03
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
2.33
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Chief Operating Officer 60 15/02/2021
Date Insider Type Main position Quantity % Market Cap.
19/7/26 Others

Chief Executive Officer

-1,361,215 3.9017%
19/7/26 Others

Director

-729,626 2.0913%
19/7/26 Others

Chief Financial Officer

-139,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%0.00%-99.45%-99.85% 387K
-0.75%+5.31%-0.56%+13.02% 48.95B
-4.38%+13.60%+22.96%+5.26% 40.75B
+3.09%-1.23%+403.66%+610.21% 38.46B
-2.49%-2.66%+6.04%+48.48% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-1.28%-1.91% - - 16.62B
-1.63%-5.58%+30.66%+125.94% 16.33B
-6.63%-3.81%-9.74%-34.84% 13.65B
-0.38%+3.42%+3.48%+9.27% 13.56B
Average -3.48%+1.62%+40.97%+81.00% 25.31B
Weighted average by Cap. -0.67%+7.20%+73.57%+123.70%

Financials

2024 2025
Net sales 491M 431M 403M 369M 691M 47B 709M 4.77B 1.87B 23.26B 1.84B 1.8B 80.41B 513M 451M 421M 386M 723M 49.14B 741M 4.99B 1.95B 24.32B 1.93B 1.88B 84.06B
Net income -108M -95.29M -88.95M -81.63M -153M -10.39B -157M -1.05B -412M -5.14B -407M -398M -17.77B -68.62M -60.3M -56.29M -51.66M -96.7M -6.57B -99.08M -667M -261M -3.25B -258M -252M -11.24B
Net Debt 424M 372M 348M 319M 597M 40.58B 612M 4.12B 1.61B 20.08B 1.59B 1.56B 69.42B 438M 384M 359M 329M 617M 41.91B 632M 4.26B 1.66B 20.74B 1.64B 1.61B 71.69B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTVQ Stock